尹家胜;胡锦江;张建海;罗馨岚;张刚;

• 1:广东医科大学附属医院整形外科

摘要(Abstract)：

皮肤恶性黑色素瘤(CMM)早期即可发生淋巴或血行转移,恶性程度高,致死率高。近年来发病率在全世界逐渐升高,早期明确诊断和判定肿瘤分期并行规范的手术治疗可明显改善预后和提高患者生存率。近年来随着分子靶向治疗和免疫治疗的优化发展,CMM的晚期治疗也获得了明显改善,但仍需继续探索。本文作者就近年来对该病诊断与治疗研究进展作如下综述。

关键词(KeyWords)： 皮肤恶性黑色素瘤;诊断;治疗

Abstract:

Keywords:

基金项目(Foundation):

作者(Authors): 尹家胜;胡锦江;张建海;罗馨岚;张刚;

DOI: 10.19593/j.issn.2095-0721.2023.01.013

参考文献(References)：

• [1] Arnold M, de Vries E, Whiteman DC, et al. Global burden of cutaneous melanoma attributable to ultraviolet radiation in 2012.INT J CANCER. 2018 2018-09-15;143(6):1305-14. PMID:29659012. DOI:10.1002/ijc.31527.
• [2] Kawakami A, Fisher DE. The master role of microphthalmiaassociated transcription factor in melanocyte and melanoma biology. LAB INVEST. 2017 2017-06-01;97(6):649-56. PMID:28263292. DOI:10.1038/labinvest.2017.9.
• [3] Feigelson HS, Powers JD, Kumar M, Carroll NM, Pathy A,Ritzwoller DP. Melanoma incidence, recurrence, and mortality in an integrated healthcare system:A retrospective cohort study.CANCER MED-US. 2019 2019-08-01;8(9):4508-16. PMID:31215776. DOI:10.1002/cam4.2252.
• [4] Hawkes JE, Truong A, Meyer LJ. Genetic predisposition to melanoma. SEMIN ONCOL. 2016 2016-10-01;43(5):591-7.PMID:27899192. DOI:10.1053/j.seminoncol.2016.08.003.
• [5] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020:GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA-CANCER J CLIN. 20212021-05-01;71(3):209-49. PMID:33538338. DOI:10.3322/caac.21660.
• [6] Wu Y, Wang Y, Wang L, Yin P, Lin Y, Zhou M. Burden of melanoma in China, 1990-2017:Findings from the 2017 global burden of disease study. INT J CANCER. 2020 2020-08-01;147(3):692-701.PMID:31671209. DOI:10.1002/ijc.32764.
• [7] CSCO黑色素瘤专家委员会.中国黑色素瘤诊治指南:2015版:中国黑色素瘤诊治指南：2015版; 2015.
• [8] Goel N, Ward WH, Yu JQ, Farma JM. Short-Term and Long-Term Management of Melanoma. 2017 2017-12-21. PMID:29461775.DOI:10.15586/codon.cutaneousmelanoma.2017.ch11.
• [9] Walker GJ, Hayward NK. Pathways to melanoma development:lessons from the mouse. J INVEST DERMATOL. 2002 2002-10-01;119(4):783-92. PMID:12406321. DOI:10.1046/j.1523-1747.2002.00217.x.
• [10] Kimbrough CW, McMasters KM, Davis EG. Principles of surgical treatment of malignant melanoma. SURG CLIN N AM. 20142014-10-01;94(5):973-88. PMID:25245962. DOI:10.1016/j.suc.2014.07.002.
• [11] Tama?C, Pintilie CT, At?n?soae IV, et al. Surgical reconstruction of post-tumoral facial defects. ROM J MORPHOL EMBRYO.2018 2018-01-20;59(1):285-91. PMID:29940639.
• [12] Ross MI, Gershenwald JE. Evidence-based treatment of earlystage melanoma. J SURG ONCOL. 2011 2011-09-01;104(4):341-53. PMID:21858828. DOI:10.1002/jso.21962.
• [13] Rigel DS, Russak J, Friedman R. The evolution of melanoma diagnosis:25 years beyond the ABCDs. CA-CANCER J CLIN.2010 2010-09-01;60(5):301-16. PMID:20671054. DOI:10.3322/caac.20074.
• [14] Grob JJ, Bonerandi JJ. The'ugly duckling'sign:identification of the common characteristics of nevi in an individual as a basis for melanoma screening. Arch Dermatol. 19981998-01-01;134(1):103-4. PMID:9449921. DOI:10.1001/archderm.134.1.103-a.
• [15] Scope A, Dusza SW, Halpern AC, et al. The"ugly duckling"sign:agreement between observers. Arch Dermatol. 20082008-01-01;144(1):58-64. PMID:18209169. DOI:10.1001/archdermatol.2007.15.
• [16] Hartman RI, Lin JY. Cutaneous Melanoma-A Review in Detection,Staging, and Management. HEMATOL ONCOL CLIN N. 20192019-02-01;33(1):25-38. PMID:30497675. DOI:10.1016/j.hoc.2018.09.005.
• [17]王永芳,谭谦.皮肤恶性黑色素瘤诊断和外科治疗的研究进展.东南大学学报（医学版）. 2021;40(5):721-5. DOI:10.3969/j.issn.1671-6264.2021.05.026.
• [18] Farberg AS, Rigel DS. A comparison of current practice patterns of US dermatologists versus published guidelines for the biopsy, initial management, and follow up of patients with primary cutaneous melanoma. J AM ACAD DERMATOL. 20162016-12-01;75(6):1193-7. PMID:27742167. DOI:10.1016/j.jaad.2016.07.051.
• [19] Swetter SM, Tsao H, Bichakjian CK, et al. Guidelines of care for the management of primary cutaneous melanoma. J AM ACAD DERMATOL. 2019 2019-01-01;80(1):208-50. PMID:30392755.DOI:10.1016/j.jaad.2018.08.055.
• [20] Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging:Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA-CANCER J CLIN. 2017 2017-11-01;67(6):472-92. PMID:29028110. DOI:10.3322/caac.21409.
• [21] Hieken TJ, Hernández-Irizarry R, Boll JM, Jones CJ. Accuracy of diagnostic biopsy for cutaneous melanoma:implications for surgical oncologists. INT J SURG ONCOL. 2013 2013-01-20;2013:196493. PMID:24102023. DOI:10.1155/2013/196493.
• [22] Mir M, Chan CS, Khan F, Krishnan B, Orengo I, Rosen T. The rate of melanoma transection with various biopsy techniques and the influence of tumor transection on patient survival. J AM ACAD DERMATOL. 2013 2013-03-01;68(3):452-8. PMID:22967665.DOI:10.1016/j.jaad.2012.08.005.
• [23] Akbani R, Akdemir KC, Aksoy BA, et al. Genomic Classification of Cutaneous Melanoma. CELL. 2015;161(7):1681-96. DOI:10.1016/j.cell.2015.05.044.
• [24]中华医学会病理学分会,中华医学会病理学分会皮肤病理学组.黑色素瘤病理诊断临床实践指南（2021版）.中华病理学杂志. 2021;50(6):572-82. DOI:10.3760/cma.j.cn112151-20210417-00299.
• [25] Gershenwald JE, Scolyer RA. Melanoma Staging:American Joint Committee on Cancer(AJCC)8th Edition and Beyond.ANN SURG ONCOL. 2018 2018-08-01;25(8):2105-10. PMID:29850954. DOI:10.1245/s10434-018-6513-7.
• [26] Conic RZ, Cabrera CI, Khorana AA, Gastman BR. Determination of the impact of melanoma surgical timing on survival using the National Cancer Database. J AM ACAD DERMATOL.2018 2018-01-01;78(1):40-6. PMID:29054718. DOI:10.1016/j.jaad.2017.08.039.
• [27] Coit DG, Thompson JA, Albertini MR, et al. Cutaneous Melanoma,Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.J NATL COMPR CANC NE. 2019 2019-04-01;17(4):367-402.PMID:30959471. DOI:10.6004/jnccn.2019.0018.
• [28] Gershenwald JE, Ross MI. Is sentinel-node biopsy superior to nodal observation in melanoma? Nat Clin Pract Oncol. 2007 2007-05-01;4(5):278-9. PMID:17389881. DOI:10.1038/ncponc0791.
• [29] Leiter U, Stadler R, Mauch C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma(DeCOG-SLT):a multicentre,randomised, phase 3 trial. LANCET ONCOL. 2016 2016-06-01;17(6):757-67. PMID:27161539. DOI:10.1016/S1470-2045(16)00141-8.
• [30] Fioranelli M, Roccia MG, Pastore C, Aracena CJ, Lotti T.Completion dissection or observation for sentinel-node metastasis in melanoma. DERMATOL THER. 2017 2017-11-01;30(6).PMID:28836714. DOI:10.1111/dth.12544.
• [31]Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma:analysis of 270 patients treated between 1985 and 1993. J CLIN ONCOL. 1999 1999-07-01;17(7):2105-16. PMID:10561265.DOI:10.1200/JCO.1999.17.7.2105.
• [32]Luke JJ, Schwartz GK. Chemotherapy in the management of advanced cutaneous malignant melanoma. CLIN DERMATOL.2013 2013-05-01;31(3):290-7. PMID:23608448. DOI:10.1016/j.clindermatol.2012.08.016.
• [33]Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. ANNU REV IMMUNOL. 2008 2008-01-20;26:677-704. PMID:18173375. DOI:10.1146/annurev.immunol.26.021607.090331.
• [34]Buchbinder EI, Desai A. CTLA-4 and PD-1 Pathways:Similarities,Differences, and Implications of Their Inhibition. AM J CLIN ONCOL-CANC. 2016 2016-02-01;39(1):98-106. PMID:26558876. DOI:10.1097/COC.0000000000000239.
• [35]Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. NEW ENGL J MED. 2010 2010-08-19;363(8):711-23. PMID:20525992. DOI:10.1056/NEJMoa1003466.
• [36]Schadendorf D, Hodi FS, Robert C, et al. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J CLIN ONCOL. 2015 2015-06-10;33(17):1889-94. PMID:25667295.DOI:10.1200/JCO.2014.56.2736.
• [37]Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. NEW ENGL J MED. 2012 2012-06-28;366(26):2443-54. PMID:22658127.DOI:10.1056/NEJMoa1200690.
• [38]Hamid O, Robert C, Daud A, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. ANN ONCOL. 2019 2019-04-01;30(4):582-8.PMID:30715153. DOI:10.1093/annonc/mdz011.
• [39] Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. NEW ENGL J MED. 2015 2015-07-02;373(1):23-34.PMID:26027431. DOI:10.1056/NEJMoa1504030.
• [40] Tawbi HA, Forsyth PA, Algazi A, et al. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. NEW ENGL J MED. 2018 2018-08-23;379(8):722-30. PMID:30134131. DOI:10.1056/NEJMoa1805453.
• [41] Richtig G, Hoeller C, Kashofer K, et al. Beyond the BRAF(V)(600E)hotspot:biology and clinical implications of rare BRAF gene mutations in melanoma patients. BRIT J DERMATOL. 20172017-10-01;177(4):936-44. PMID:28278349. DOI:10.1111/bjd.15436.
• [42] Boni A, Cogdill AP, Dang P, et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. CANCER RES. 2010 2010-07-01;70(13):5213-9. PMID:20551059. DOI:10.1158/0008-5472.CAN-10-0118.
• [43] Robert C, Grob JJ, Stroyakovskiy D, et al. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.NEW ENGL J MED. 2019 2019-08-15;381(7):626-36. PMID:31166680. DOI:10.1056/NEJMoa1904059.
• [44] Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J.Hepatotoxicity with combination of vemurafenib and ipilimumab.NEW ENGL J MED. 2013 2013-04-04;368(14):1365-6. PMID:23550685. DOI:10.1056/NEJMc1302338.
• [45] Hu-Lieskovan S, Mok S, Homet MB, et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E)melanoma. SCI TRANSL MED. 20152015-03-18;7(279):241r-279r. PMID:25787767. DOI:10.1126/scitranslmed.aaa4691.
• [46] Ascierto PA, Ferrucci PF, Fisher R, et al. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. NAT MED. 2019 2019-06-01;25(6):941-6. PMID:31171878. DOI:10.1038/s41591-019-0448-9.
• [47] Ribas A, Lawrence D, Atkinson V, et al. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAFmutant melanoma. NAT MED. 2019 2019-06-01;25(6):936-40.PMID:31171879. DOI:10.1038/s41591-019-0476-5.
• [48] Xue X, Liu Y, Chen X, et al. Pan-cancer analysis identifies NT5E as a novel prognostic biomarker on cancer-associated fibroblasts associated with unique tumor microenvironment.FRONT PHARMACOL. 2022 2022-12-07;13. DOI:10.3389/fphar.2022.1064032.
• [49] Peng J, Wang T, Yue C, Luo X, Xiao P. PGAM5:A necroptosis gene associated with poor tumor prognosis that promotes cutaneous melanoma progression. FRONT ONCOL. 2022 2022-11-29;12. DOI:10.3389/fonc.2022.1004511.